ArticleBMC infectious diseases2025
A novel model for predicting the risk of liver cirrhosis in people living with HIV/HBV coinfection: a study based on proteomic analysis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEasily accessible clinical warning signals of liver cirrhosis for optimal management in people living with HIV/HBV co-infection remains limited. Using proteomic techniques, a risk prediction model for liver cirrhosis through the screening of differentially expressed proteins (DEPs) in people living with HIV/HBV coinfection was developed.
methodsQuantitative liquid chromatography-mass spectrometry (LC–MS) was used to identify DEPs in plasma collected from HIV/HBV co-infected patients with or without liver cirrhosis. The annotation information of DEPs were obtained by mapping identified proteins to the Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes(KEGG), and Disease Ontology(DO) databases. Differential expression levels of plasma L-selectin(CD62L) were validated in HIV/HBV co-infected patients.
resultsProteomic profiling of 13 matched patient pairs with HIV/HBV coinfection revealed 111 differentially expressed proteins (DEPs) associated with liver cirrhosis. Functional analysis showed significant enrichment in immune processes and the Complement and Coagulation Cascades pathway, underpinning the chronic inflammatory and fibrotic aspects of the disease. A diagnostic signature derived from these DEPs was developed, with a model containing IGHV5-37 and L-selectin showing high predictive value. Critically, the elevated plasma level of L-selectin in cirrhosis was confirmed in a separate validation cohort of 90 patients, underscoring its clinical relevance.
conclusionsOur findings demonstrate that cirrhosis in HIV/HBV coinfected patients is characterized by a specific plasma proteomic profile. From this profile, we derived and validated a diagnostic model, highlighting L-selectin as a key validated biomarker. This model holds significant promise for development into a clinical assay to improve the detection and management of liver disease in this high-risk population. CLINICAL TRIAL: Not applicable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.